Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9162432 | 0.82 | KMT2A (0.40) | KMT2AMEN1ALDH1A1TSHRHTR7 | |
| SCHEMBL6496004 | 0.81 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1TSHRHTR7 | |
| SCHEMBL9160614 | 0.77 | KMT2A (0.39) | KMT2AMEN1ALDH1A1TSHRHTR7 | |
| SCHEMBL16061634 | 0.70 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1TSHRHSD17B3 | |
| SCHEMBL224280 | 0.69 | CYP1A2 (0.36) | KMT2AMEN1ALDH1A1TSHRHSD17B3 | |
| SCHEMBL17436661 | 0.67 | BRD4 (0.43) | KMT2AMEN1ALDH1A1TSHRHSD17B3 | |
| SCHEMBL9160662 | 0.67 | MEN1 (0.34) | KMT2AMEN1ALDH1A1TSHRPOLB | |
| SCHEMBL19095188 | 0.66 | BRD4 (0.38) | KMT2AMEN1ALDH1A1TSHRHSD17B3 | |
| SCHEMBL21172599 | 0.66 | BRD4 (0.38) | KMT2AMEN1ALDH1A1TSHRHSD17B3 | |
| SCHEMBL17436722 | 0.66 | BRD4 (0.38) | KMT2AMEN1ALDH1A1TSHRHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881753-B2 | Potassium channel inhibitors and method | BRISTOL-MYERS SQUIBB CO. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1109544-A4 | POTASSIUM CHANNEL INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040192710-A1 | Potassium channel inhibitors and method | LLOYD JOHN (US) | 2004-09-30 | — | — | US | disclosed |
| US-6784189-B2 | SULFONAMIDE COMPOUNDS CONTAINING BICYCLIC RING STRUCTURE ARE USEFUL AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040067944-A1 | Potassium channel inhibitors and method | LLOYD JOHN (US) | 2004-04-08 | — | — | US | disclosed |
| US-20040058931-A1 | Potassium channel inhibitors and method | LLOYD JOHN (US) | 2004-03-25 | — | — | US | disclosed |
| US-6511977-B1 | For preventing or treating cardiac arrhythmia or atrial arrhythmia | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-28 | — | — | US | disclosed |
| EP-1109544-A1 | POTASSIUM CHANNEL INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6150356-A | BENZOPYRANS AND DERIVATIVES ARE USED AS POTASSIUM CHANNEL INHIBITORS AND THUS ARE USEFUL AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000012077-A1 | POTASSIUM CHANNEL INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5401848-A | Indane and quinoline derivatives | E. R. SQUIBB & SONS, INC. (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0488616-A1 | Indane and quinoline derivatives | E.R. SQUIBB & SONS, INC. (US) | 1992-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058931-A1 | Potassium channel inhibitors and method | KCNH2, KCNJ2, KCNB1 | KMT2A 1569/4885MEN1 3529/4885ALDH1A1 824/4885 |
| US-20040192710-A1 | Potassium channel inhibitors and method | KCNH2, KCNJ2, KCNB1 | KMT2A 1569/4885MEN1 3529/4885ALDH1A1 824/4885 |
| US-20040067944-A1 | Potassium channel inhibitors and method | KCNH2, KCNJ2, KCNB1 | KMT2A 1569/4885MEN1 3529/4885ALDH1A1 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.